Vitamin K is as a group of molecules serving as cofactors of protein carboxylation that leads to creation of gamma-carboxyglutamic acid residues which enable calcium bonding[@b1]. Several vitamin K-dependent proteins are known. They are involved in coagulation, preservation of bone mineral density and protection against vascular calcification[@b2][@b3]. It is also postulated that vitamin K plays an important role in the central nervous system[@b4]. Thus, vitamin K deficiency has a range of consequences, of which loss of bone mineral density is the most prominent, as it manifests even before blood coagulation factors production becomes altered[@b5].

One of two main substrates of vitamin K-dependent carboxylation used for vitamin K status assessment is protein induced by vitamin K absence-II (PIVKA-II), the other being osteocalcin[@b6]. Plasma PIVKA-II concentrations were shown to inversely correlate with plasma phylloquinone concentrations[@b7]. PIVKA-II levels assessment and direct vitamin K concentrations measurements have shown that vitamin K deficiency is prevalent in patient populations as different as newborn infants[@b8], children with chronic liver disease[@b9], hemodialyzed patients[@b10], cystic fibrosis patients[@b11][@b12], the institutionalized elderly[@b13], and is also a consequence of treatment with vitamin K antagonists[@b14]. Vitamin K deficiency has also been reported in chronic gastrointestinal disorders[@b15], including inflammatory bowel diseases (IBD)[@b16][@b17]. However, to authors\' best knowledge, vitamin K status has not been investigated in children with IBD so far.

The aim of this study was to assess the prevalence of vitamin K deficiency and its correlates in children with Crohn\'s disease (CD) and ulcerative colitis (UC).

Results
=======

The median PIVKA-II serum concentration \[interquartile range\] in IBD equaled 2 ng/mL \[1.3--3.1\]; it was 2.3 \[1.3--3.5\] in Crohn\'s disease, and 1.9 \[1.3--2.7\] in ulcerative colitis. PIVKA-II levels were equal to or higher than 2 ng/mL in 34 of 63 patients (54.0%) with CD and 21 of 48 patients (43.7%) with UC. Basic clinical features in CD and UC patients with and without vitamin K deficiency are shown in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, respectively. The PCDAI and Truelove-Witts scores in patients with and without vitamin K deficiency are illustrated in [Fig. 1](#f1){ref-type="fig"}.

The prevalence of vitamin K deficiency was 28.6% in children with CD receiving infliximab and 61.2% in children with CD not receiving biological therapy (χ^2^, p = 0.03). The median PCDAI scores in CD patients receiving infliximab and in children not treated with infliximab did not differ (14.5 \[12.5--17.5\] and 20.0 \[10.0--42.5\], respectively). Significant differences in body mass Z-scores of vitamin K-sufficient and vitamin K-deficient CD patients were also noted (p = 0.04).

Higher prevalence of vitamin K deficiency in CD patients treated with corticosteroids was statistically non-significant (χ^2^, p = 0.09). Body mass Z-score values in vitamin K-deficient children with UC were not significantly lower than in vitamin K-sufficient children with UC (p = 0.07).

PIVKA-II levels positively correlated with PCDAI scores (σ = 0.37, p = 0.03). PIVKA-II concentrations did not correlate with longer CD duration (σ = −0.22, p = 0.08) and patients\' body mass Z-scores (σ = 0.17, p = 0.18). No variables correlated with PIVKA-II levels in children with UC.

In univariate logistic regression models the probability of vitamin K deficiency increased with higher PCDAI scores (OR = 1.04, 95% CI 1.01--1.07, p = 0.02). Similarly, higher body mass Z-scores predicted vitamin K deficiency in children with CD (OR = 1.64, 95% CI 1.01--2.65, p = 0.04). For all other continuous variables analyzed p was 0.09 or greater. Multiple regression analyses in CD and UC did not yield any significant results (p ≥ 0.10 for all factors).

Discussion
==========

This is the first study to document vitamin K deficiency in pediatric IBD population. Every second IBD patient was vitamin K-deficient. Vitamin K deficiency was more common in CD than in UC. This finding is consistent with results previously obtained in adults. However, the data obtained in this study suggest that vitamin K deficiency could be more frequent in children with UC than in adults with UC. The percentage of patients with undercarboxylated osteocalcin levels above cutoff value reported in a report by Kuwabara et al.[@b16] was 92% in CD (N = 47) and 36% in UC patients (N = 40). Nakajima et al.[@b17] who investigated a group of 47 CD patients, 40 UC patients and 41 healthy volunteers found higher undercarboxylated osteocalcin levels in CD patients and no evidence of vitamin K deficiency in adults with UC. Vitamin K deficiency in adult IBD patients was also described by Krasinski et al. They reported high PIVKA-II concentrations in 13 out of 34 patients with CD and in 4 out of 17 patients with UC[@b15].

The reason for vitamin K deficiency in IBD remains unclear. It may be hypothesized that vitamin K deficiency results from undernutrition and/or malabsorption caused by IBD and utilized treatments. This notion is supported by the evidence for vitamin E co-deficiency in IBD[@b14] and for antibiotic-induced vitamin K metabolism disturbance[@b18][@b19][@b20]. Shea et al. pointed out that vitamin K may have anti-inflammatory properties[@b21]. Given this assumption is true, vitamin K deficiency should lead to a more severe IBD course and, consequently, more pronounced undernutrition and malabsorption. Indeed, PCDAI scores positively correlated with PIVKA-II levels, indicating greater prevalence of vitamin K deficiency in patients with more active CD. Although the results obtained do not seem to lend support to the hypothesis that vitamin K deficiency plays a causative role in the pathogenesis of IBD, it needs to be underscored that this is a separate question that the study presented did not address.

Vitamin K deficiency was less common in patients receiving infliximab. This fact points to a possibility that vitamin K status in CD reflects the intensity of inflammation. Further research is needed to clarify whether biological therapy influences vitamin K status in children with Crohn\'s disease. In fact, no studies on the relationship between anti-TNF therapies and vitamin K status have been published so far.

It is interesting that while body mass Z-scores of vitamin K-deficient children with CD were higher compared to those who were vitamin K-sufficient, body mass Z-scores in vitamin K-deficient patients with UC were lower than in those who were vitamin K-sufficient. The reasons for higher Z-scores in vitamin K-deficient patients with CD remain unclear.

The study was limited in several aspects. Firstly, vitamin K status was not analyzed directly. It remains an open question if direct measurement of vitamin K concentration in the blood would be more clinically relevant than the measurement of PIVKA-II concentration. Different vitamin K levels may lead to vitamin K sufficiency in different patients. Thus, the estimation of vitamin K status using PIVKA-II concentrations may present an advantage in that it reflects a lack of vitamin K cofactory function enabling for carboxylation of vitamin K-dependent compounds. However, there are factors other than vitamin K status that influence PIVKA-II concentration and it cannot be ruled out that they are linked to IBD activity.

The cross-sectional character of the study did not allow for analysis of PIVKA-II concentrations\' evolution along with disease activity changes. No data on dietary intake of vitamin K were available. If there are seasonal variations of vitamin K status, they could have been a source of bias, as the patients were examined at different time points.

Vitamin K deficiency was highly prevalent in pediatric IBD. In CD patients it correlated with a lack of infliximab treatment, a higher pediatric CD activity, and higher body mass Z-scores. Relation of vitamin K deficiency to pediatric IBD clinical course and treatment demand further research.

Methods
=======

A total of 111 children with inflammatory bowel disease (IBD) were included in the study (67 M, 44 F, age range 6--18). Sixty-three were treated for CD and 48 for UC. Diagnoses were established on the basis of clinical, histological, endoscopic and/or radiographic criteria[@b22][@b23][@b24][@b25]. The inclusion criteria were: CD or UC diagnosed according to the aforementioned standards, and age of 18 years at most. The exclusion criteria were: liver disease not related to IBD, cancer, anti-vitamin K treatment, pregnancy, and diagnosis of AIDS.

Information on age, body mass and height, disease activity and duration, C-reactive protein (CRP) serum concentration, the number of hospitalizations for IBD, the number of IBD exacerbations, and the treatment in use were gathered using a questionnaire distributed among clinicians participating in the study. Disease activity in CD and UC was described using the Pediatric Crohn\'s Disease Activity Index (PCDAI)[@b25] and Truelove-Witts scores[@b26], respectively. Z-scores for body mass and height were calculated using data relating to the local population[@b27].

Vitamin K status was assessed using PIVKA-II concentration in patients\' blood sera. PIVKA-II concentrations were determined by enzyme immunoassay (Asserachrom PIVKA-II, Roche Diagnostic, Rotkreuz, Switzerland). It was considered that values ≥ 2 ng/mL (detectable values) indicated vitamin K deficiency[@b9][@b28].

Statistical analyses were performed in the R environment (version 2.14.1; The R Foundation for Statistical Computing, Vienna, Austria) and using STATISTICA 10 (StatSoft Inc., Tulsa, USA). Wilcoxon rank sum test was used to compare subgroups of CD and CU patients who were vitamin K sufficient and vitamin K deficient. Results obtained from logistic regression analysis, multiple regression analysis, Spearman\'s correlation test, Pearson\'s chi-squared test and Fisher\'s exact test are appropriately labeled. The level of significance was set at p \< 0.05.

The study was conducted in accordance with the Declaration of Helsinki. Informed and written consent was obtained from patients\' parents and patients who were at least 16 years old. The study design was approved by Poznan University of Medical Sciences Bioethical Committee, Poznan, Poland (decision no 53/11).
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###### Basic clinical features in Crohn\'s disease patients with and without vitamin K deficiency.

                                                                          Vitamin K deficiency                                     
  ----------------------------------------------------------------- -------------------------------- ----------------------------- ---------------
  Number of patients                                                           29 (46.0%)                     34 (54.0%)                   
  Age (years)                                                             15.0 \[12.0--16.2\]             16.0 \[14.0--17.0\]           0.19
  **Body mass (Z-score)**                                            **−1.1 \[−1.5**-- **(−0.5)\]**   **−0.4 \[−1.3**--**0.0\]**      **0.04**
  Height (Z-score)                                                         −0.4 \[−1.0--0.2\]             −0.3 \[−0.9--0.3\]            0.41
  Disease duration (months)                                                19.0 \[7.0--27.0\]             15.5 \[6.2--33.5\]            0.59
  Ileal involvement                                                              75.9%                           84.8%                0.57 χ^2^
  **Pediatric Crohn**\'**s Disease Activity Index score**             **15.0 \[10.0**--**25.0\]**     **22.5 \[10.6**--**50.0\]**     **0.04**
  C-reactive protein serum concentration relative to cutoff value           1.2 \[0.5--3.1\]               1.5 \[0.4--2.7\]             0.71
  Hospitalizations                                                          1.0 \[0.5--2.0\]               1.5 \[1.0--2.0\]             0.68
  Exacerbations                                                             1.0 \[1.0--2.0\]               1.0 \[0.25--2.0\]            0.84
  Corticosteroid treatment                                                       34.5%                           55.9%                0.09 χ^2^
  Immunosuppressive treatment                                                    58.6%                           55.9%                0.93 χ^2^
  **Infliximab**                                                        **34.5%**(10 out of 29)         **11.8%**(4 out of 34)      **0.03 χ^2^**

###### Basic clinical features in ulcerative colitis patients with and without vitamin K deficiency.

                                                                Vitamin K deficiency                            
  ----------------------------------------------------------- ------------------------ ------------------------ ---------------------------
  Number of patients                                                 27 (56.3%)               21 (43.7%)                      
  Age (years)                                                   14.0 \[12.0--16.0\]      14.0 \[13.0--16.0\]               0.98
  Body mass (Z-score)                                          −0.7 \[−1.0-- (−0.1)\]   −1.3 \[−1.4-- (−0.2)\]             0.07
  Height (Z-score)                                               −0.7 \[−1.1--0.1\]       −0.9 \[−1.7--0.6\]               0.73
  Disease duration (months)                                     24.0 \[11.0--44.0\]      19.0 \[11.0--42.0\]               0.79
  Truelove-Witts score                                            2.0 \[0.5--4.0\]         4.0 \[1.0--6.0\]                0.26
  C-reactive protein concentration relative to cutoff value       0.5 \[0.1--1.4\]         0.1 \[0.1--0.8\]                0.21
  Hospitalizations                                                0.0 \[0.0--1.0\]         1.0 \[0.0--1.0\]                0.25
  Exacerbations                                                   0.0 \[0.0--1.0\]         1.0 \[0.0--1.0\]                0.19
  Corticosteroid treatment                                             25.9%                    14.3%            0.29 Fishers\' exact test
  Immunosuppressive treatment                                          25.9%                    38.1%                    0.37 χ^2^
